Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

proton pump inhibitor use

PreclinicalSmall molecule

CChangi General Hospital

proton pump inhibitor use is one of 2 small molecule programs targeting Hypomagnesemia. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypomagnesemiaActive, not recruiting

HypomagnesemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Hypomagnesemia

#DrugCompanyPhaseTrials

Magnesium

SSpherium Biomed

proton pump inhibitor use

CChangi General Hospital

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypomagnesemia1 trial

Hypomagnesemia Associated With Proton-Pump Inhibitor Use

Completed·—··NCT04426994·211,672 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for proton pump inhibitor use. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — proton pump inhibitor use compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for proton pump inhibitor use. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Changi General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CChangi General Hospital

Related News